Program at a glance
The ISOO 2022 Congress will take place from Friday, June 17 - Tuesday, June 21, 2022 in Leiden, The Netherlands. Please click on the image below for the full program at a glance. An overview of the sessions can be found below.
Friday, June 17, 2022
08:59 a.m. - 10:30 a.m.
Johannes Vermeer and Frans van Mieris
S1 Scientific Collaborations: Horizon2020 CURE UM
Moderators:
Niels Brouwer (The Netherlands), Martyna Elas (Poland), B. Ewa Jagalska (The Netherlands) & Sergio Roman-Roman (France)
08:59 a.m. - 09:00 a.m.
Introducing CURE UM
Presenter:
Sergio Roman-Roman (France)
09:00 a.m. - 09:08 a.m.
Protein tyrosine kinase activity in primary uveal melanoma is associated with the presence of tumour-infiltrating leukocytes
Presenter:
Annemijn Wierenga (The Netherlands)
09:08 a.m. - 09:16 a.m.
Novel therapies for uveal melanoma
Presenter:
Kseniya Glinkina (The Netherlands)
09:16 a.m. - 09:24 a.m.
Tumor-infiltrating T cells can successfully be expanded from primary uveal melanoma after separation from their tumor environment
Presenter:
Gülcin Gezgin (The Netherlands)
09:24 a.m. - 09:32 a.m.
Characterization of immune cell infiltrates and immune checkpoints in primary UM and liver metastases
Presenter:
Raymond Barnhill (France)
09:32 a.m. - 09:40 a.m.
The high-risk replacement histopathologic growth pattern in UM liver metastases
Presenter:
Raymond Barnhill (France)
09:40 a.m. - 09:48 a.m.
Tumour pigmentation and chromosome 3 are related in uveal melanoma
Presenter:
Maria Chiara Gelmi (The Netherlands)
09:48 a.m. - 09:56 a.m.
Ferroptosis inhibition by melanin promotes metastatic colonization of melanoma cells
Presenter:
B. Ewa Jagalska (The Netherlands)
09:56 a.m. - 10:04 a.m.
Melanization of human UM tumors affects their metastasizing in mice
Presenter:
Małgorzata Szczygieł (Poland)
10:04 a.m. - 10:12 a.m.
Uveal melanoma cell lines grown as 3D tumor spheroids
Presenter:
Anna Kozińska (Poland)
10:12 a.m. - 10:20 a.m.
Vitreous fluid as a novel liquid biopsy for primary uveal melanoma
Presenter:
Rogier J. Nell (The Netherlands)
10:20 a.m. - 10:28 a.m.
Ocular toxicity in uveal melanoma patients treated in the first year of a new proton therapy center
Presenter:
Marina Marinkovic (The Netherlands)
10:30 a.m. - 11:00 a.m.
Coffee break
11:00 a.m. - 12:30 p.m.
Johannes Vermeer and Frans van Mieris
S2 International Collaborations in Ocular Oncology
Moderators:
Rana'a Al Jamal (Finland), Brenda Gallie (Canada), Rogier J. Nell (The Netherlands) & Vicktoria (vicky) Vishnevskia-Dai (Israel)
11:00 a.m. - 11:08 a.m.
PRIMA (PRegnancy In uveal Melanoma Analysis) study - A European OOG MultiCenter study
Presenter:
Shahar Frenkel (Israel)
11:08 a.m. - 11:16 a.m.
Clinical phenotype of germline BAP1 mutation mmong pediatric uveal melanomas
Presenter:
Rana'a Al Jamal (Finland)
11:16 a.m. - 11:24 a.m.
Nevus of Ota: Suggestion for new ocular classification
Presenter:
Vicktoria (vicky) Vishnevskia-Dai (Israel)
11:24 a.m. - 11:32 a.m.
Capturing uveal melanoma (UM) global practice patterns and clinical outcomes in the collaborative ocular melanoma natural history (OMNi; NCT04588662) study
Presenter:
Richard Carvajal (United States)
11:32 a.m. - 11:40 a.m.
Euracan collaboration
Presenters:
Ellen Kapiteijn (The Netherlands) & Sophie Piperno-Neumann (France)
11:40 a.m. - 11:48 a.m.
An integrative, prospective clinical and tissue database for uveal melanoma
Presenter:
Lauren Dalvin (United States)
11:48 a.m. - 11:56 a.m.
VISION (Virtual Information System to Improve Outcomes and Networks) - Advancing Ocular Melanoma (OM) research through patient powered data collection
Presenter:
Sara Selig (United States)
11:56 a.m. - 12:04 p.m.
Developing an ocular oncology fellowship program
Presenter:
Hatem Krema (Canada)
12:04 p.m. - 12:12 p.m.
Stage IV uveal melanoma: Pooled data from of an international registry
Presenter:
Gaurav Garg (India)
12:12 p.m. - 12:20 p.m.
Update on international Rb database
Presenter:
Brenda Gallie (Canada)
12:20 p.m. - 12:28 p.m.
High-level MYCN-amplified RB1-proficient retinoblastoma tumors retain distinct molecular signatures
Presenter:
Josephine Dorsman (The Netherlands)
EURbG Business Meeting
11:00 a.m. - 12:30 p.m.
Willem van de Velde
Rb FAM (parallel session, members only)
12:30 p.m. - 01:30 p.m.
Lunch break
01:30 p.m. - 02:00 p.m.
Johannes Vermeer and Frans van Mieris
S3 Lex van der Eb Lecture
01:30 p.m. - 01:40 p.m.
Development Leiden Bio Science Park
Presenter:
Bart van Zijll Langhout (The Netherlands)
01:40 p.m. - 02:00 p.m.
Lex van der Eb Lecture
Presenter:
J. William Harbour (United States)
Moderator:
Martine Jager (The Netherlands)
EURbG Business Meeting
01:30 p.m. - 03:30 p.m.
Willem van de Velde
EURbG Business Meeting (parallel session, members only)
02:00 p.m. - 03:30 p.m.
Johannes Vermeer and Frans van Mieris
S4 Genetics and Epigenetics in Oncology
Moderators:
Shahar Frenkel (Israel), J. William Harbour (United States), Emine Kiliç (The Netherlands) & Marc-Henri Stern (France)
02:00 p.m. - 02:10 p.m.
Aging and epigenetic changes
Presenter:
Bruce Ksander (United States)
02:10 p.m. - 02:18 p.m.
Genetics and prognostic value of TERT promoter mutations in conjunctival melanoma
Presenter:
Natasha van Poppelen (The Netherlands)
02:18 p.m. - 02:26 p.m.
Contribution of MYC copy number gain and mutations in tumor suppressor genes to the oncogenesis of ocular adnexal sebaceous carcinomas
Presenter:
Cornelia Peterson (United States)
02:26 p.m. - 02:34 p.m.
Primary UM display intratumoral heterogeneity; HES6, a driver of metastatic disease
Presenter:
Corine Bertolotto (France)
02:34 p.m. - 02:42 p.m.
Disease-specific mortality among patients with local recurrence from uveal melanoma is primarily driven by chromosomes 3 and 8q
Presenter:
Mette Bagger (Denmark)
02:42 p.m. - 02:50 p.m.
Chromosome 3 and 8q aberrations in uveal melanoma show greater impact on survival in patients with light iris versus dark iris color
Presenter:
Martine Jager (The Netherlands)
02:50 p.m. - 02:58 p.m.
Different pigmentation risk loci for high-risk, monosomy 3 and low-risk, disomy 3 uveal melanomas
Presenter:
Marc-Henri Stern (France)
02:58 p.m. - 03:06 p.m.
Impact of PRAME status on Gene Expression Profile to predict metastasis in UM: interim analysis of the COOG2
Presenter:
Alison Skalet (United States)
03:06 p.m. - 03:14 p.m.
Leveraging single cell genomics and epigenomics to provide accurate prognostication for patients with uveal melanoma
Presenter:
Mathieu Bakhoum (United States)
03:14 p.m. - 03:22 p.m.
Aqueous humor-derived MYD88 L265P mutation analysis in vitreoretinal lymphoma: A potential less-invasive method for diagnosis and treatment response assessment
Presenter:
Hakan Demirci (United States)
03:22 p.m. - 03:30 p.m.
Ocular adnexal large B-cell lymphoma: Prevalence and prognostic value of MYD88 and CD79B mutations, double-hit lymphoma, and double-expressor phenotype
Presenter:
Marina Knudsen Kirkegaard (Denmark)
03:30 p.m. - 04:00 p.m.
Coffee break
04:00 p.m. - 05:00 p.m.
Johannes Vermeer and Frans van Mieris
S5 Immunology in Ocular Oncology
Moderators:
Marlana Orloff (United States), Sophie Piperno-Neumann (France), Manuel Rodrigues (France) & Robert Verdijk (The Netherlands)
04:00 p.m. - 04:08 p.m.
Combining Checkpoint Inhibitors and liver perfusion
Presenter:
Thais Tong (The Netherlands)
04:08 p.m. - 04:16 p.m.
PERIO-01: A phase 1/1b trial of hepatic arterial infusion of SD-101 +/- checkpoint inhibition in metastatic uveal melanoma using pressure-enabled drug delivery
Presenter:
Sapna Patel (United States)
04:16 p.m. - 04:24 p.m.
Macrophage Inhibitory Factor (MIF) Inhibition as a novel adjuvant treatment strategy for high risk uveal melanoma (UM)
Presenter:
Alex Rai (United States)
04:24 p.m. - 04:32 p.m.
Predominance of CD8+ T cell infiltration is most pronounced in high-risk primary uveal melanoma
Presenter:
Kalijn Bol (The Netherlands)
04:32 p.m. - 04:40 p.m.
MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients
Presenter:
Manuel Rodrigues (France)
04:40 p.m. - 04:48 p.m.
Tebentafusp in UM
Presenter:
Sophie Piperno-Neumann (France)
04:48 p.m. - 04:56 p.m.
Metastatic uveal melanoma patients with long term survival after tebentafusp
Presenter:
Marlana Orloff (United States)
EURbG Business Meeting
04:00 p.m. - 05:00 p.m.
Willem van de Velde
EURbG Business Meeting (parallel session, members only)
05:00 p.m. - 07:00 p.m.
Golden Dome Building - LUMC Building 3
Welcome Reception